4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 6.2% – Time to Sell?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) shares traded down 6.2% during trading on Monday . The company traded as low as $13.75 and last traded at $13.76. Approximately 551,066 shares traded hands during mid-day trading, a decline of 34% from the average session volume of 830,914 shares. The stock had previously closed at $14.67.

Analyst Upgrades and Downgrades

FDMT has been the subject of several recent research reports. Chardan Capital upgraded 4D Molecular Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. Finally, B. Riley Financial reissued a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $29.62.

4D Molecular Therapeutics Stock Down 6.2%

The company has a market cap of $760.10 million, a price-to-earnings ratio of -5.23 and a beta of 2.73. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05. The business has a fifty day moving average of $12.21 and a two-hundred day moving average of $10.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The business had revenue of $3.78 million during the quarter, compared to analyst estimates of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. As a group, equities analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

Insiders Place Their Bets

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 9,810 shares of the stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total transaction of $117,720.00. Following the transaction, the insider directly owned 8,617 shares of the company’s stock, valued at $103,404. This trade represents a 53.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider David Kirn sold 12,415 shares of 4D Molecular Therapeutics stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $10.05, for a total transaction of $124,770.75. Following the completion of the sale, the insider owned 871,737 shares in the company, valued at approximately $8,760,956.85. This trade represents a 1.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 198,574 shares of company stock worth $2,220,985 in the last three months. 7.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of FDMT. Dynamic Technology Lab Private Ltd acquired a new stake in 4D Molecular Therapeutics in the 1st quarter worth about $39,000. Wexford Capital LP acquired a new stake in shares of 4D Molecular Therapeutics in the third quarter worth approximately $41,000. AQR Capital Management LLC acquired a new stake in shares of 4D Molecular Therapeutics in the first quarter worth approximately $46,000. Daiwa Securities Group Inc. increased its position in shares of 4D Molecular Therapeutics by 3,362.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after purchasing an additional 6,186 shares in the last quarter. Finally, Rangeley Capital LLC acquired a new position in 4D Molecular Therapeutics in the 2nd quarter valued at $48,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.